Skip to main content
Premium Trial:

Request an Annual Quote

Radboud UMC, NimaGen Partner to Develop Targeted Sequencing Kits

NEW YORK (GenomeWeb) – Radboud University Medical Center and NimaGen said today that they have agreed to codevelop target enrichment library prep kits for next-generation sequencing.

Specifically, the partners plan to develop kits based on single-molecule molecular inversion probes (smMIPs). NimaGen will manufacture the kits to be sold under its proprietary EasySeq technology line. Alexander Hoischen, an assistant professor at Radboud UMC, said in a statement that smMIPs have "key advantages, including ease of use and high accuracy."

The agreement builds on a previous collaboration under which Radboud and NimaGen codeveloped an oncology hotspot kit and a kit to analyze the BRCA1 and BRCA2 genes. NimaGen also manufactures and sells those kits under its EasySeq line.

The new collaboration "will enable us to integrate the expertise of Radboud UMC into NimaGen's growing portfolio of NGS products," NimaGen CEO Ruud van der Steen added.

The partners also noted that they are now developing a pharmacogenomics panel and a Lynch syndrome panel. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more